If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 7 of 7
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
Objective
Study of tandem, bispecific anti-CD19 anti-CD20 CAR-T cells for Patients with Relapsed and/or Refractory B Cell Malignancies
Protocol No
IIT-SHAH-IL7-IL15-CD20-19
Categories
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Objective
A phase 1 Study evaluating NX-5948, a BTK Degrader in Adults with Relapsed Refractory B-cell Malignancies
Protocol No
NURIX-NX-5948-301
Categories
A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B
Objective
Phase II MB-CART2019.1 for R/R DLBCL
Protocol No
MILTENYI-MB-CART2019-1-DLBCL
Categories
Phase I Study of LV20.19 CAR T-Cells in Combination with Pirtobrutinib for Relapsed, Refractory B-Cell Malignancies
Objective
Phase I Study of LV20.19 CAR T-Cells in Combination with Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Protocol No
IIT-SHAH-PIRTO
Categories
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination with Other Agents in Patients with Relapsed or Refractory B-Cell Malignancies
Objective
Study of BGB-16673 in combination with other agents for patients with R/R B-cell malignancies
Protocol No
BEIGENE-BGB-16673-104
Categories
A Single-Arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi)
Objective
A Phase 2 Study Evaluating NX-5948 in Relapsed/Refractory CLL/SLL
Protocol No
NURIX-NX-5948-201
Categories
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
Objective
To find out if this approach is better or worse than the usual approach for DLBCL patients receiving CAR T-cell therapy. The usual approach for Relapsed/Refractory DLBCL patients is follow-up visits with no further therapy.
Protocol No
SWOG-S2114
Categories